scholarly journals Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Glenn Wagner ◽  
Karen Chan Osilla ◽  
Jeffrey Garnett ◽  
Bonnie Ghosh-Dastidar ◽  
Laveeza Bhatti ◽  
...  
Keyword(s):  
Treatment Adherence ◽  
Sustained Virologic Response ◽  
Treatment Completion ◽  
Patient Characteristics ◽  
Pegylated Interferon ◽  
Virologic Response ◽  
Hcv Treatment ◽  
Hiv Patients ◽  
Poor Treatment ◽  
Treatment Onset

Background. Hepatitis C (HCV) treatment efficacy among HIV patients is limited by poor treatment adherence and tolerance, but few studies have examined the psychosocial determinants of treatment adherence and outcomes.Methods. Chart abstracted and survey data were collected on 72 HIV patients who had received pegylated interferon and ribavirin to assess correlates of treatment adherence, completion, and sustained virologic response (SVR).Results. Nearly half (46%) the sample had active psychiatric problems and 13% had illicit drug use at treatment onset; 28% reported <100% treatment adherence, 38% did not complete treatment (mostly due to virologic nonresponse), and intent to treat SVR rate was 49%. Having a psychiatric diagnosis was associated with nonadherence, while better HCV adherence was associated with both treatment completion and SVR.Conclusions. Good mental health may be an indicator of HCV treatment adherence readiness, which is in turn associated with treatment completion and response, but further research is needed with new HCV treatments emerging.

scholarly journals Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection

2020 ◽  
Author(s):  
Lisette A P Krassenburg ◽  
Wayel R Zanjir ◽  
Firas Georgie ◽  
Emily Stotland ◽  
Harry L A Janssen ◽  
...  
Keyword(s):  
Disease Severity ◽  
Clinical Benefit ◽  
Sustained Virologic Response ◽  
Event Rate ◽  
Surrogate Endpoint ◽  
Pegylated Interferon ◽  
Causal Link ◽  
Virologic Response ◽  
Event Free Survival ◽  
Free Survival

Abstract Background The causal link of sustained virologic response (SVR) with outcome has been challenged. With improved SVR rates with direct-acting antivirals (DAAs), the benefit of SVR would be expected to diminish if the association with outcome is not causal. Methods Data were collected for patients starting treatment with interferon (IFN) or DAAs between June 2006 and December 2016. To control for disease severity, criteria for the IDEAL (Individualized Dosing Efficacy vs. Flat Dosing to Assess Optimal Pegylated Interferon Therapy) trial determined IFN-eligibility. Clinical events were decompensation, hepatocellular carcinoma, liver transplantation, and all-cause mortality. Results In 1078 IDEAL-eligible patients, 1306 treatments occurred (52% IFN, 49% DAAs). Cirrhosis was present in 30% DAAs vs 21% IFN (P &lt; .001). SVR was 97% with DAAs vs 52% with IFN (P &lt; .0001). The 24-month cumulative event-free survival was 99% for IFN and 97% for DAAs with SVR (P = .08) and 96% and 75%, respectively, for non-SVR (P = .01). SVR was associated with improved event-free survival with an adjusted hazard ratio of 0.21 (95% confidence interval, .06–.71; P = .01). Using inverse probability of treatment weighting to match IFN nonresponders with DAA-treated patients, the 24-month event-rate was 1.1% with DAAs compared to 3.4% in IFN nonresponders (P = .005), highlighting the clinical benefit of maximizing SVR. Conclusions In IFN-eligible patients, SVR is more commonly achieved with DAAs and confers a similar clinical benefit as in those treated with IFN. The reduced event-rate with DAAs compared to IFN, despite similar disease severity, confirm that SVR alters prognosis leading to improved clinical outcomes.

1213 Erythropoietin maintains ribavirin dose and sustained virologic response during HCV treatment

Hepatology ◽  
2003 ◽  
Vol 38 ◽  
pp. 744-744 ◽  
Author(s):  
L SENKBEIL ◽  
J MOSS ◽  
P GAGLIO ◽  
L DOVE ◽  
S LOBRITTO ◽  
...  
Keyword(s):  
Sustained Virologic Response ◽  
Virologic Response ◽  
Hcv Treatment

M1781 Rapid Virologic Response Predicts Sustained Virologic Response in Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin Therapy

2009 ◽  
Vol 136 (5) ◽  
pp. A-836-A-837
Author(s):  
Shahzad Sarwar ◽  
Masood Iqbal ◽  
P Aiden McCormick ◽  
Cliona O'Farrelly ◽  
John E. Hegarty
Keyword(s):  
Hepatitis C ◽  
Sustained Virologic Response ◽  
Pegylated Interferon ◽  
Virologic Response ◽  
Rapid Virologic Response

scholarly journals Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Colette Smit ◽  
◽  
Joop Arends ◽  
Lars Peters ◽  
Antonella d’Arminio Montforte ◽  
...  
Keyword(s):  
Sustained Virologic Response ◽  
Virologic Response ◽  
Hcv Treatment
Sign in / Sign up

Export Citation Format

Share Document